Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans

Peter C. Butler, Joanne Chou, W. Bradford Carter, Yeng Nung Wang, Bing Hong Bu, Ding Chang, Jaw Kang Chang, Robert A. Rizza

Research output: Contribution to journalArticle

279 Citations (Scopus)

Abstract

Recent interest has focused on the potential role of amylin in the pathogenesis of non-insulin-dependent diabetes mellitus (NIDDM). This 37-amino acid peptide is found in extracellular amyloid deposits in ∼50% of pancreatic islets of patients with NIDDM and has been shown to inhibit skeletal muscle glycogen synthesis in vitro, lmmunocytochemical studies have colocalized amylin and insulin within ß-cell secretory granules in nondiabetic humans, provoking the following questions. Is amylin cosecreted with insulin? Are circulating amylin concentrations higher in patients with NIDDM either before or after food ingestion? To answer these questions, we developed a sensitive and specific immunoassay to measure plasma concentrations of amylin in humans. Use of this assay indicated that, in lean nondiabetic subjects, glucose ingestion resulted in an increase (P < 0.001) in the plasma concentration of amylin (from 2.03 ± 0.22 to 3.78 ± 0.39 pM) and insulin (from 48.3 ± 3.1 to 265 ± 44 pM). There was a significant correlation between the concentrations of insulin and amylin (r = 0.74, P < 0.001) and the increase in insulin and amylin concentration (r = 0.65, P < 0.005). Fasting concentrations of amylin did not differ in diabetic and weight-matched nondiabetic subjects and showed a similar pattern of change after ingestion of a mixed meal. We conclude that amylin is secreted in response to ingestion of either glucose or a mixed meal and circulates at concentrations that do not differ in patients with NIDDM and nondiabetic subjects. It remains to be determined whether amylin at physiological concentrations influences carbohydrate metabolism and if so whether its effects differ in diabetic and nondiabetic humans.

Original languageEnglish (US)
Pages (from-to)752-756
Number of pages5
JournalDiabetes
Volume39
Issue number6
StatePublished - Jun 1990
Externally publishedYes

Fingerprint

Islet Amyloid Polypeptide
Type 2 Diabetes Mellitus
Meals
Eating
Insulin
Glucose
Amyloid Plaques
Secretory Vesicles
Carbohydrate Metabolism
Glycogen
Islets of Langerhans
Immunoassay
Fasting
Skeletal Muscle

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Butler, P. C., Chou, J., Carter, W. B., Wang, Y. N., Bu, B. H., Chang, D., ... Rizza, R. A. (1990). Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans. Diabetes, 39(6), 752-756.

Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans. / Butler, Peter C.; Chou, Joanne; Carter, W. Bradford; Wang, Yeng Nung; Bu, Bing Hong; Chang, Ding; Chang, Jaw Kang; Rizza, Robert A.

In: Diabetes, Vol. 39, No. 6, 06.1990, p. 752-756.

Research output: Contribution to journalArticle

Butler, PC, Chou, J, Carter, WB, Wang, YN, Bu, BH, Chang, D, Chang, JK & Rizza, RA 1990, 'Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans', Diabetes, vol. 39, no. 6, pp. 752-756.
Butler PC, Chou J, Carter WB, Wang YN, Bu BH, Chang D et al. Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans. Diabetes. 1990 Jun;39(6):752-756.
Butler, Peter C. ; Chou, Joanne ; Carter, W. Bradford ; Wang, Yeng Nung ; Bu, Bing Hong ; Chang, Ding ; Chang, Jaw Kang ; Rizza, Robert A. / Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans. In: Diabetes. 1990 ; Vol. 39, No. 6. pp. 752-756.
@article{d5881b4e208041ab9a624bbefe607045,
title = "Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans",
abstract = "Recent interest has focused on the potential role of amylin in the pathogenesis of non-insulin-dependent diabetes mellitus (NIDDM). This 37-amino acid peptide is found in extracellular amyloid deposits in ∼50{\%} of pancreatic islets of patients with NIDDM and has been shown to inhibit skeletal muscle glycogen synthesis in vitro, lmmunocytochemical studies have colocalized amylin and insulin within {\ss}-cell secretory granules in nondiabetic humans, provoking the following questions. Is amylin cosecreted with insulin? Are circulating amylin concentrations higher in patients with NIDDM either before or after food ingestion? To answer these questions, we developed a sensitive and specific immunoassay to measure plasma concentrations of amylin in humans. Use of this assay indicated that, in lean nondiabetic subjects, glucose ingestion resulted in an increase (P < 0.001) in the plasma concentration of amylin (from 2.03 ± 0.22 to 3.78 ± 0.39 pM) and insulin (from 48.3 ± 3.1 to 265 ± 44 pM). There was a significant correlation between the concentrations of insulin and amylin (r = 0.74, P < 0.001) and the increase in insulin and amylin concentration (r = 0.65, P < 0.005). Fasting concentrations of amylin did not differ in diabetic and weight-matched nondiabetic subjects and showed a similar pattern of change after ingestion of a mixed meal. We conclude that amylin is secreted in response to ingestion of either glucose or a mixed meal and circulates at concentrations that do not differ in patients with NIDDM and nondiabetic subjects. It remains to be determined whether amylin at physiological concentrations influences carbohydrate metabolism and if so whether its effects differ in diabetic and nondiabetic humans.",
author = "Butler, {Peter C.} and Joanne Chou and Carter, {W. Bradford} and Wang, {Yeng Nung} and Bu, {Bing Hong} and Ding Chang and Chang, {Jaw Kang} and Rizza, {Robert A.}",
year = "1990",
month = "6",
language = "English (US)",
volume = "39",
pages = "752--756",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "6",

}

TY - JOUR

T1 - Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans

AU - Butler, Peter C.

AU - Chou, Joanne

AU - Carter, W. Bradford

AU - Wang, Yeng Nung

AU - Bu, Bing Hong

AU - Chang, Ding

AU - Chang, Jaw Kang

AU - Rizza, Robert A.

PY - 1990/6

Y1 - 1990/6

N2 - Recent interest has focused on the potential role of amylin in the pathogenesis of non-insulin-dependent diabetes mellitus (NIDDM). This 37-amino acid peptide is found in extracellular amyloid deposits in ∼50% of pancreatic islets of patients with NIDDM and has been shown to inhibit skeletal muscle glycogen synthesis in vitro, lmmunocytochemical studies have colocalized amylin and insulin within ß-cell secretory granules in nondiabetic humans, provoking the following questions. Is amylin cosecreted with insulin? Are circulating amylin concentrations higher in patients with NIDDM either before or after food ingestion? To answer these questions, we developed a sensitive and specific immunoassay to measure plasma concentrations of amylin in humans. Use of this assay indicated that, in lean nondiabetic subjects, glucose ingestion resulted in an increase (P < 0.001) in the plasma concentration of amylin (from 2.03 ± 0.22 to 3.78 ± 0.39 pM) and insulin (from 48.3 ± 3.1 to 265 ± 44 pM). There was a significant correlation between the concentrations of insulin and amylin (r = 0.74, P < 0.001) and the increase in insulin and amylin concentration (r = 0.65, P < 0.005). Fasting concentrations of amylin did not differ in diabetic and weight-matched nondiabetic subjects and showed a similar pattern of change after ingestion of a mixed meal. We conclude that amylin is secreted in response to ingestion of either glucose or a mixed meal and circulates at concentrations that do not differ in patients with NIDDM and nondiabetic subjects. It remains to be determined whether amylin at physiological concentrations influences carbohydrate metabolism and if so whether its effects differ in diabetic and nondiabetic humans.

AB - Recent interest has focused on the potential role of amylin in the pathogenesis of non-insulin-dependent diabetes mellitus (NIDDM). This 37-amino acid peptide is found in extracellular amyloid deposits in ∼50% of pancreatic islets of patients with NIDDM and has been shown to inhibit skeletal muscle glycogen synthesis in vitro, lmmunocytochemical studies have colocalized amylin and insulin within ß-cell secretory granules in nondiabetic humans, provoking the following questions. Is amylin cosecreted with insulin? Are circulating amylin concentrations higher in patients with NIDDM either before or after food ingestion? To answer these questions, we developed a sensitive and specific immunoassay to measure plasma concentrations of amylin in humans. Use of this assay indicated that, in lean nondiabetic subjects, glucose ingestion resulted in an increase (P < 0.001) in the plasma concentration of amylin (from 2.03 ± 0.22 to 3.78 ± 0.39 pM) and insulin (from 48.3 ± 3.1 to 265 ± 44 pM). There was a significant correlation between the concentrations of insulin and amylin (r = 0.74, P < 0.001) and the increase in insulin and amylin concentration (r = 0.65, P < 0.005). Fasting concentrations of amylin did not differ in diabetic and weight-matched nondiabetic subjects and showed a similar pattern of change after ingestion of a mixed meal. We conclude that amylin is secreted in response to ingestion of either glucose or a mixed meal and circulates at concentrations that do not differ in patients with NIDDM and nondiabetic subjects. It remains to be determined whether amylin at physiological concentrations influences carbohydrate metabolism and if so whether its effects differ in diabetic and nondiabetic humans.

UR - http://www.scopus.com/inward/record.url?scp=0025287442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025287442&partnerID=8YFLogxK

M3 - Article

VL - 39

SP - 752

EP - 756

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 6

ER -